Boston Scientific Corporation $BSX Shares Purchased by Costello Asset Management INC

Costello Asset Management INC raised its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 38.9% during the fourth quarter, HoldingsChannel reports. The fund owned 57,973 shares of the medical equipment provider’s stock after acquiring an additional 16,230 shares during the quarter. Boston Scientific comprises approximately 1.8% of Costello Asset Management INC’s holdings, making the stock its 12th largest position. Costello Asset Management INC’s holdings in Boston Scientific were worth $5,528,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. Murphy & Mullick Capital Management Corp raised its stake in shares of Boston Scientific by 200.0% in the 3rd quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock valued at $25,000 after purchasing an additional 170 shares in the last quarter. FWL Investment Management LLC acquired a new position in Boston Scientific in the second quarter worth about $26,000. United Community Bank increased its holdings in Boston Scientific by 115.7% in the third quarter. United Community Bank now owns 274 shares of the medical equipment provider’s stock valued at $27,000 after buying an additional 147 shares during the last quarter. Colonial Trust Co SC grew its position in shares of Boston Scientific by 502.2% in the 3rd quarter. Colonial Trust Co SC now owns 277 shares of the medical equipment provider’s stock worth $27,000 after acquiring an additional 231 shares in the last quarter. Finally, Bangor Savings Bank boosted its holdings in Boston Scientific by 94.7% in the fourth quarter. Bangor Savings Bank now owns 292 shares of the medical equipment provider’s stock worth $28,000 after purchasing an additional 142 shares during the period. 89.07% of the stock is owned by institutional investors and hedge funds.

Boston Scientific Trading Down 4.7%

NYSE:BSX opened at $53.89 on Friday. The company has a market capitalization of $80.08 billion, a P/E ratio of 22.55, a P/E/G ratio of 1.04 and a beta of 0.62. The stock’s 50 day moving average price is $65.95 and its 200 day moving average price is $83.68. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.08 and a current ratio of 1.90. Boston Scientific Corporation has a 52 week low of $53.63 and a 52 week high of $109.50.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.79 by $0.01. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The firm had revenue of $5.20 billion during the quarter, compared to analysts’ expectations of $5.19 billion. During the same period in the previous year, the company earned $0.75 earnings per share. The company’s revenue was up 11.6% compared to the same quarter last year. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. On average, research analysts forecast that Boston Scientific Corporation will post 3.38 EPS for the current fiscal year.

Analysts Set New Price Targets

BSX has been the subject of a number of research reports. UBS Group decreased their target price on Boston Scientific from $120.00 to $105.00 and set a “buy” rating for the company in a research note on Tuesday, March 17th. JPMorgan Chase & Co. decreased their target price on shares of Boston Scientific from $135.00 to $100.00 and set an “overweight” rating for the company in a research report on Thursday, February 5th. Canaccord Genuity Group decreased their price target on Boston Scientific from $109.00 to $71.00 and set a “buy” rating for the company in a research note on Thursday, April 23rd. Citigroup lowered their price objective on shares of Boston Scientific from $94.00 to $87.00 and set a “buy” rating on the stock in a research note on Tuesday, April 7th. Finally, Daiwa Securities Group lowered Boston Scientific from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, April 29th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, Boston Scientific currently has an average rating of “Moderate Buy” and a consensus target price of $93.91.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.